2013-10-02 15:19:29 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to BioDelivery Sciences International, Inc. (BDSI) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering BioDelivery Sciences International, Inc. (BDSI). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential BioDelivery Sciences International, Inc. investor.
Report Summary: BioDelivery Sciences International, Inc. is a low quality company with a negative outlook. BioDelivery Sciences International, Inc. has weak business growth and is run by inefficient management. The trend in BioDelivery Sciences International, Inc. fair value exchange rate against its closest rated-competitor, Biostar Pharmaceuticals Inc, has been appreciating over the past 2 weeks. When compared to its closest competitor, BioDelivery Sciences International, Inc. shows similar overvaluation and is equally likely to underperform the market.
The report breaks down
the Total StockMark into its three components - business, management and price, performing an in-depth analysis of BioDelivery Sciences International, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.